Lauren Nardella
Latest From Lauren Nardella
ICCS President Hill On Growing Regulatory Confidence In Alternative Testing Methodologies
In the year since its establishment, the International Collaboration on Cosmetics Safety has worked to engage with regulators as they build frameworks for assessing cosmetic safety without animal tests. ICCS president and CEO Erin Hill discusses current challenges and what lies ahead.
Hawaii Contemplates Measures To Increase Access To Sunscreens Following Sunscreen Bans
Hawaii looks to “ease the burden” of finding reef-safe sunscreens by distributing it to sunseekers at beaches. The proposed legislation comes roughly three years after the Aloha State began prohibiting sale of oxybenzone- or octinoxate-containing sunscreen products due to concerns about potential harm to coral.
Where Is Science (And US EPA) On Sunscreen Ingredient Environmental Hazards?
The US Environmental Protection Agency “is not currently planning a full scope ERA that would include the fate and distribution of UV filters in the environment because the data are currently not available to do so in a defensible manner,” an agency spokesperson said.
Federal Ban On PFAs In Cosmetics Could Ensure National Uniformity; It Also Could Drive Litigation
While studies are limited regarding the human health effects of PFAS in cosmetic products, efforts to prohibit their use continue gaining steam at the state and federal levels, which could lead to increased litigation.
California DTSC To Focus On Nail Product Regs With Greatest Impact – Safer Consumer Product Leaders
Following the release of a comprehensive survey of chemicals of concern in nail products on the California market, the state’s Department of Toxic Substances Control has a better idea of nail product ingredient use, which could help inform future rulemaking.
‘We Can’t Go Back In Time’: CIR Panel Grapples With Prostaglandins Review Without Animal Test Data
In its safety assessment of two prostaglandin analogues, the Expert Panel for Cosmetic Ingredient Safety determined that certain read-across data from potentially related ingredients were not enough to extrapolate and apply to a prostaglandin review. This and more from the panel's 4-5 December meeting.